Daclatasvir + Sofosbuvir plan official its effective treatment rates higher, so the Sofosbuvir + ledipasvir or Sofosbuvir coalition after the RIBAVIRIN or interferon, patients and a better choice. Actually Daclatasvir without FDA pre-market has been widely accepted among patients, because it has been approved in the eu and Japan and other countries and curative effect is very good. So that some southeast Asian generic drug companies compete to generic, such as Bangladesh, Laos has in generic card he wei, after India, gradually attracted the attention of hepatitis c patients from all over the world
In fact, the best treatment plan is: Daclatasvir + Sofosbuvir, but from economic considerations, usually use Sofosbuvir plus RIBAVIRIN in suggest that type 2. Type we use Sofosbuvir + ledipasvir from economic considerations, it is also dedicated to research and development of type 1, at present, India have been listed, for three and six model, I'm afraid it is better to choose the combination of Daclatasvir + Sofosbuvir the safest, of course, if the economy allows, other classification is also the best with it.